Compare UL & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UL | SNY |
|---|---|---|
| Founded | 1930 | 1994 |
| Country | United Kingdom | France |
| Employees | 96092 | 74846 |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.1B | 104.5B |
| IPO Year | N/A | N/A |
| Metric | UL | SNY |
|---|---|---|
| Price | $60.60 | $42.34 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $58.00 |
| AVG Volume (30 Days) | ★ 4.1M | 3.5M |
| Earning Date | 03-12-2026 | 04-23-2026 |
| Dividend Yield | ★ 4.04% | 3.47% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.53 | $3.49 |
| Revenue Next Year | $3.78 | $6.10 |
| P/E Ratio | $14.29 | ★ $6.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.75 | $40.89 |
| 52 Week High | $74.98 | $52.68 |
| Indicator | UL | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 62.46 | 43.39 |
| Support Level | $60.16 | $42.30 |
| Resistance Level | $61.14 | $48.76 |
| Average True Range (ATR) | 0.78 | 0.73 |
| MACD | 0.36 | -0.15 |
| Stochastic Oscillator | 89.92 | 35.86 |
Unilever is a diversified beauty, wellbeing, and personal care (51% of 2025 sales by value), homecare (23%), and packaged food (26%) company. Its brands include Dove personal-care products, Knorr soups and sauces, Hellmann's mayonnaise, Axe and Rexona deodorants, and TRESemmé haircare. The firm has been acquisitive in recent years; notable purchases include Paula's Choice, Liquid I.V., Horlicks, and Wild deodorants. The company derives 58% of its sales from emerging markets and 42% from developed markets. The US is its largest market, accounting for around 20% of sales, followed by India, which accounts for 11% of sales.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.